Field of Invention

The invention relates to a stable tablet composition of fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative as an active ingredient and its preparation.

Background of Invention

Fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]-propane-l,3-diol) is a sphingosine-1 phosphate (SIP)) receptor modulator. Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Chemically, it is know as (2-amino-2-[2-(4-octylphenyl)ethyl]-propane-l,3-diol) and is structurally represented as given below.

Fingolimod is approved for treating patients with relapsing forms of multiple sclerosis by reducing the frequency of clinical exacerbations and to delay the accumulation of physical disability. Fingolimod sequesters lymphocytes in lymph nodes, preventing them from moving to the central nervous system for autoimmune responses in multiple sclerosis.

Fingolimod is currently marketed as an immediate release capsule for the treatment of multiple sclerosis under the trade name Gilenya® in the US. This formulation contains 0.5 mg equivalent of fingolimod base in the form of the hydrochloride salt and magnesium stearate, mannitol as inactive ingredients.

US 5,604,229 first discloses fingolimod and its pharmaceutically acceptable salts and process for its preparation. US 6,004,565 discloses method of manipulating lymphocyte traffic in a mammal by administering fingolimod hydrochloride.

US 8,324,283 discloses a solid pharmaceutical composition for oral administration comprising fingolimod and a sugar alcohol. The sugar alcohol may be mannitol, maltitol, inositol, xylitol or lactitol.

US 2008/0096972 discloses a pharmaceutical organic concentrate formulation comprising fingolimod or a salt thereof in an organic solvent of ethanol in propylene glycol.

US 2010/0040678 & US 2012/288559 discloses a pharmaceutical composition comprising fingolimod with a coating comprising polymers resins and metal oxides.

US 2010/0267675 discloses dosage forms containing fingolimod and one or more excipients selected from fillers, binders, disintegrants, lubricants, flow regulators, matrix formers, plasticizers, flavouring agents and sweeteners.

US 2011/0229501 discloses a pharmaceutical composition of hydrochloride salt of fingolimod in the form of a hydrate.

US2013/0034603 discloses a process of preparing a pharmaceutical composition of fingolimod comprising preparing an intimate admixture of fingolimod and a solid surfactant and optionally combining the admixture with one or more excipients.

US 2013/0095177 discloses a method of preparation of an intermediate containing fingolimod and excipients, having particles size of all the intermediate particles less than 250 μm and greater than 0.6μm.

US 2013/0102682 discloses an intermediate containing fingolimod and matrix material, wherein the fingolimod is present in the matrix material in the form of a solid solution.

US 2013/0102683 discloses a method of preparing an intermediate comprising melt processing fingolimod and a matrix former.

US 2012/0328664 discloses a concentrate for dilution comprising a SIP receptor modulator or agonist and propylene glycol.

WO 2013/091704 discloses a pharmaceutical composition comprising fingolimod, calcium lactate pentahydrate and optionally a lubricant.

WO2012/135561 discloses a solid oral pharmaceutical composition comprising fingolimod, a filler and a cyclodextrin as a stabilizer.

Preparation of pharmaceutical formulation of fingolimod is not an easy task as the drug itself either in its free form; in a pharmaceutically acceptable salt form or as a phosphate derivative possess properties that can cause processing problems during preparation. The stability and uniformity of pharmaceutical compositions containing fingolimod is heavily dependent on the choice of excipients used in the formulation, and the process by which the formulation is prepared. Fingolimod is unstable in presence of many excipients due to the reactivity of aminopropane-l,3-diol group and produce degradation products in the final formulation.
Capsule dosage form has disadvantage of microbial contamination. Further, the acceptability of tablets is better than capsules and free from hazards of Bovine Spongiform Encephalopathy (BSE) and Transmissible Spongiform Encephalopathy (TSE). In general tablets are stable than capsules.

The currently marketed dosage form of Fingolimod is immediate release capsule. However, conventionally tablets are preferred compared to capsules. It is disclosed that that the chances of developing stable tablets of fingolimod are limited due to nature of API and its potential to interact with several tablet excipients. For this reason, Gilenya is developed with only two excipients (mannitol and magnesium stearate).

Fingolimod active pharmaceutical ingredient as such is highly stable, however it is not compatible with many excipients and hence, when processed into solid dosage forms stability problems are encountered. Therefore, fingolimod is marketed as a capsule dosage form with shelf life of 24 months are less and storage under controlled conditions. However, the desirable means of marketing widely acceptable product is without restricted storage and longer shelf life.
To overcome the above problems, the present inventors in their continuous efforts found that the stable tablets of fingolimod can be developed using appropriate formulation approaches.
Objective of the Invention

The object of the present invention is to provide a stable tablet dosage form of Fingolimod or a pharmaceutically acceptable salt thereof.

Another object of the invention is to provide a stable tablet dosage form comprising fingolimod, wherein the total impurity of the composition is less than the total impurity of the composition containing sugar alcohol.

Summary of Invention

Accordingly, the present invention provides a stable tablet dosage form comprising fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative.

Accordingly, the present invention provides a stable tablet dosage form comprising fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative and a zwitterion as a stabilizer.

Detailed Description of the Invention

The main embodiment of the present invention is to provide a stable tablet dosage form of fingolimod, which comprises fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative and a zwitterion.

The zwitterion is used as a stabilizer in the composition and is present in an amount ranging from about 0.1 to 95% by weight of total composition, preferably from 5 to 95% by weight of total composition. The weight ratio of Fingolimod to zwitterion is from 90:10 to 1:99.

The zwitterion according to the present invention is selected from an amino acids, a phospholipid, and a sulfobetaine (NS).

The non-limiting examples of amino acids as Zwitterion are selected from glycine, arginine, histidine, alanine, isoleucine, leucine, asparagine, lysine, aspartic acid, methionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, valine, ornithine, proline, selenocysteine, serine, tyrosine or a combination thereof. The preferable amino acids are glycine, leucine or a mixture thereof.

Zwitterion phospholipids constitute any phospholipid with ionizable groups where the net charge is zero. The non-limiting examples of zwitterion phospholipid are phosphatidyl choline, phosphatidyl ethanolamine, sphingomyeline, lysophatidylethanolamine, cerebrosides, dimyristoylphosphatidyl choline, dipalmitotylphosphatidyl choline, distearyloylphosphatidyl choline, dielaidoylphosphatidyl choline, dioleoylphosphatidyl choline, dilauryloylphosphatidyl choline, 1 -myristoyl-2-palmitoyl phosphatidyl choline, l-palmitoyl-2-myristoyl phosphatidyl choline, 1-palmitoyl-phosphatidyl choline, 1-stearoyl-2-palmitoyl phosphatidyl choline, dimyristoyl phosphatidyl ethanolamine, dipalmitoyl phosphatidyl ethanolamine, brain sphingomyelin, dipalmitoyl sphingomyelin, distearoyl sphingomyelin, and mixtures thereof. Preferably, the zwitterion phospholipid is phosphatidyl choline.

Suitable Sulfobetaine zwitterion is dimethylsulfonioacetate.

In another embodiment, the stable composition of Fingolimod further comprises one or more pharmaceutically acceptable excipients selected from diluent, binder, disintegrant, surafactant, glidant, lubricant and the like.

Fingolimod or its pharmaceutically acceptable salts or phosphate derivatives thereof of the present invention may be in form of amorphous, crystalline or solvated form such as anhydrous, hydrate and the like.

The term "pharmaceutically acceptable salt" include inorganic or organic acids such as hydrochloric, hydrobromic, nitric, sulfuric, phosphoric, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, oxalic, pamoic, pantothenic, succinic, tartaric, p-toluenesulfonic acid and the like.

The term "comprising", which is synonymous with "including", "containing", or "characterized by" here is defined as being inclusive or open-ended, and does not exclude additional, unrecited elements or method steps, unless the context clearly requires otherwise.

In a preferred embodiment, the present invention provides a pharmaceutical composition comprising fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative and glycine as a stabilizer. The glycine used in the present invention is having a mean particle size less than 250um, preferably less than 160um. The dgo of glycine particle size is less than 400um, preferably less than 350um.

In yet another embodiment, the present invention provides a pharmaceutical composition comprising fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative and a zwitterion as a stabilizer, wherein the total impurity of the composition is less than the total impurity of the composition containing only sugar alcohol.

In another preferred embodiment, the present invention provides a pharmaceutical composition comprising fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative and glycine or leucine or a mixture thereof as a stabilizer, wherein the total impurity of the composition is less than the total impurity of the composition containing only a sugar alcohol.

Suitable diluents according to the present invention are selected from microcrystalline cellulose, powdered cellulose, lactose (anhydrous or monohydrate), compressible sugar, fructose, dextranes, other sugars such as mannitol, sorbitol, lactitol, saccharose or a mixture thereof, siliconised microcrystalline cellulose, calcium hydrogen phosphate, calcium carbonate, calcium lactate or mixtures thereof. A preferred further diluent that also causes reduced sticking properties of tablets to the equipment used for tabletting is silica, preferably colloidal or fumed silica. Preferably, the diluent is selected from microcrystalline cellulose, lactose monohydrate or mixture thereof. The diluent is present in amount from about 10% to about 80%, preferably from about 5%, to about 50%, by weight of the composition.

Suitable binders according to the present invention are selected from polyvinyl pyrollidone, polyvinylpyrrolidone/vinyl acetate copolymer, polyvinyl alcohol, polymers of acrylic acid and its salts, starch, celluloses and celluloses derivatives like methylcellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxyl propyl cellulose, ethylhydroxyethylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose etc., maltrin, sucrose solution, dextrose solution, acacia, tragacanth, locust bean gum, gelatine, guar gum, starch, pregelatinised starch, partially hydrolysed starch, alginates, xanthan or polymethacrylate, or mixtures thereof. It is preferable to use a binder with good water solubility. Preferably, the binder is selected from hydroxypropyl cellulose and povidone. The binding agent is present in the composition in an amount of from about 1% to about 25%, preferably from about 1%, to about 15%, more preferably from about 1% to about 10%.

Suitable lubricants according to the present invention are selected from stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulphate, hydrogenated vegetable oil, hydrogenated castor oil, sodium stearyl fumarate, macrogols, or mixtures thereof. Preferably, the lubricant is selected from stearic acid, magnesium stearate, calcium stearate and sodium lauryl sulphate, more preferably from stearic acid, magnesium stearate and calcium stearate. The lubricant is present in an amount from about 0.5% to about 5% by weigh of the composition.

Suitable disintegrants according to the present invention are selected from crospovidone, modified starches especially sodium starch glycolate, carmellose especially croscarmellose sodium, carboxymethylcellulose calcium and the mixture thereof. The disintegrant is present in the composition in an amount of from about 1% to about 20 %, preferably from about 1% to about 15%, more preferably from about 1% to about 10%.

The composition can also comprises glidants such as colloidal silica (e. g. Aerosil®), magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.

Suitable surfactants according to the present invention are selected from cyclodextrin and its derivatives, lipophilic substances or any combination thereof. Non-limiting examples of surfactants include non-ionic, anionic, cationic, amphoteric or zwitterionic or any combination thereof. Non-ionic surfactant is preferable.

In another embodiment, the stable composition of the present invention is free of sugar alcohol.
In a preferred embodiment, the present invention provides a stable tablet dosage form comprising fingolimod or a pharmaceutically acceptable salt thereof or a phosphate derivative, 5 to 95% by weight of a zwitterion and one or more pharmaceutically acceptable excipients.

In another preferred embodiment, the present invention provides a stable tablet dosage form comprising fingolimod or a pharmaceutically acceptable salt thereof or a phosphate derivative, 5 to 95% by weight of a zwitterion selected from glycine, arginine, histidine, alanine, isoleucine, leucine, asparagine, lysine, aspartic acid, methionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, valine, ornithine, proline, selenocysteine, serine, tyrosine or a combination thereof and one or more pharmaceutically acceptable excipients.

In yet another preferred embodiment, the present invention provides a stable tablet dosage form comprising fingolimod or a pharmaceutically acceptable salt thereof or a phosphate derivative, 5 to 95% by weight of a zwitterion and at lease one pharmaceutically acceptable excipient selected from

a) diluent selected from microcrystalline cellulose, lactose monohydrate or mixture thereof;
b) binder selected from hydroxypropyl cellulose or povidone;
c) lubricants selected from stearic acid, magnesium stearate or calcium stearate.
d) disintegrant selected from crospovidone, sodium starch glycolate, croscarmellose sodium,
e) glidant selected from colloidal silica or talc.

The tablet dosage form contain about 0.05 to about 20 mg, preferably, about 0.1 to about 10 mg of fingolimod, most preferably about 0.2 to about 5mg of fingolimod.

Optionally, tablets can be coated with conventional materials used for film coating, i.e. as described in "Pharmaceutical Coating Technology", 1995, edited by Graham Cole. Film coating formulations usually contain the following components: polymer(s), plasticizer (s), colourant(s) /opacifier(s), vehicle(s). In film coating suspension the minor quantities of flavours, surfactants and waxes can be used. The polymers used in film coating are either cellulose derivatives, such as the cellulose ethers, or acrylic polymers and copolymers. Occasionally encountered are high molecular weight polyethylene glycols, polyvinyl pyrrolidone, polyvinyl alcohol and waxy materials.

Typical cellulose ethers are hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose and methylcellulose. Acrylic polymers comprise a group of synthetic polymers with diverse functionalities. Some of them can be further modified to enhance swelling and permeability by the incorporation of materials such as water soluble cellulose ethers and starches in order to ensure complete disintegration / dissolution of the film.

The commonly used plasticizers can be categorized into three groups: polyols (glycerol, propylene glycol and macrogols), organic esters (phthalate esters, dibutyl sebacetate, citrate esters, and triacetin), oils/glycerides (castor oil, acetylated monoglycerides, and fractionated coconut oil).

Colourants/opacifiers are classified into several groups: organic dyes and their lakes, inorganic colours, natural colours. Combination of different materials form each group can be combined in defined ratios. Film coating suspensions can be used as ready-to-make preparations which are available on the market.

Film coating dispersion can be prepared using solvents selected from water, alcohols, ketones, esters, chlorinated hydrocarbons and the like or mixture thereof.

A composition of coating suspension (calculated on dry material) is particularly preferred which comprises: 1-99% by weight of polymer, preferably 1- 95% of polymer; 1-50% by weight of plasticizer, preferably 1-40% of plasticizer; 0.1-20% of colourant/opacifier, preferably 0.1- 10% of colourant/opacifier, all the percentage are based on the total weight of coating material.
The present pharmaceutical compositions are prepared by known technological procedures, e.g. direct blending and capsule filing, direct compression, dry granulation or wet granulation.

The composition preparations of the invention can be produced by compressing a mixture of the drug substance of the invention with excipients. For example, one method for the production direct compression which includes mixing the fingolimod with the materials for the preparation by a suitable mixer, and followed by compressing the mixture into tablets. Other methods include a dry granulating step to produce granules using dry granulating machines or roller compacters, and a wet granulating step using water, ethanol and solutions containing binders, to produce granules for compressing into tablets.

In one aspect, the present invention relates to a process for producing a tablet dosage form composition, comprising:

(a) mixing fingolimod or a pharmaceutical acceptable salts or a phosphate derivative thereof with zwitterion;
(b) optionally, granulating the mixture obtained in the step (a);
(c) mixing the mixture from the step (a) or, optionally, from the step (b) with a lubricant and
(d) compressing the blend into tablets.

In another aspect, the present invention relates to a process for producing a pharmaceutical composition, comprising:

(a) mixing fingolimod or a pharmaceutical acceptable salts or a phosphate derivative thereof with zwitterion;
(b) optionally, granulating the mixture obtained in the step (a); and
(c) optionally, mixing the mixture from the step (a) or (b) with one or more additional excipients like diluents, disintegrants, surfactants;
(d) lubricating the mixture of step (c); and
(e) finally compressing the mixture of step (d) into tablets.

In another embodiment, at least 75 % of fingolimod is dissolved from the pharmaceutical composition in a 0.1N HC1 + 0.2% sodium lauryl sulphate in 30 minutes, when dissolution is performed using USP apparatus I (basket), at a temperature of the dissolution medium of 37±0.5°C, speed of rotation of the basket 100 rpm and volume of the dissolution medium 500 ml. Preferably the drug release rate of the composition of the invention is more than 70% in 15 minutes, above 80%, e. g. 90%, over 30 minutes, and above 95% over 45 minutes.

The tablet dosage form of the invention containing fingolimod is preferably administered once daily in an amount of 0.1 to 5 mg/day.

The tablet dosage form of the present invention are useful in (a) treatment and prevention of organ or tissue transplant rejection, for example for the treatment of the recipients of heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants, and the prevention of graft-versus-host disease, such as sometimes occurs following bone marrow transplantation; particularly in the treatment of acute or chronic alio- and xenograft rejection or in the transplantation of insulin producing cells, e.g. pancreatic islet cells; (b) treatment and prevention of autoimmune disease or of inflammatory conditions, e.g. chronic long term diseases, e.g. multiple sclerosis, arthritis (for example rheumatoid arthritis), inflammatory bowel disease, hepatitis, etc.; treatment and/or prevention of viral myocarditis and viral diseases caused by viral myocarditis, including hepatitis and AIDS. Multiple sclerosis takes several forms, with new symptoms occurring either in discrete attacks (relapsing forms) or slowly accumulating over time (progressive forms). As herein defined, multiple sclerosis refers, but is not limited to, relapsing remitting multiple sclerosis (RRMS) or primary progressive multiple sclerosis (PPMS), e.g. RR.MS.

In one embodiment, tablet dosage form comprising fingolimod or a pharmaceutically acceptable salt thereof of the invention has a comparable bioavailability to the commercial form of fingolimod. In one preferred embodiment, a pharmaceutical composition comprising fingolimod is bioequivalent to commercial dosage form of fingolimod.

The following experimental details are set forth to aid in understanding of the invention, and are not intended, and should not be construed, to limit in any way the invention set forth in the claims that follow thereafter. A person skilled in the art will readily recognize the various modifications and variations that may be performed without altering the scope of the present invention. Such modifications and variations are encompassed within the scope of the invention and the examples do not in any way limit the scope of the invention.
Example 1

Manufacturing procedure for Fl:

1. Fingolimod HC1 and small amount of Glycine was dissolved in water,
2. Remaining amount of Glycine and PVP K was loaded in RMG and mixed,
3. Granulated the step-2 materials by using step-1 solution.
4. Wet mass of step -3 was dried to obtain granules,
5. Blended the granules with extragrnaular talc and
6. Compressed the blend into tablets.

Example 2

Procedure:

1. Fingolimod HC1 and small amount of Glycine was dissolved in water
2. Remaining amount of Glycine and PVP, MCC, Plasdone XL 10 was loaded in RMG and mixed,
3. Granulated the step-2 materials by using step-1 solution.
4. Wet mass of step -3 was dried to obtain granules,
5. Blended the granules obtained in step-4 with extragranular MCC and talc and
6. Compressed the blend into tablets.

Example 3

Procedure:

1. Fingolimod HC1 and small amount of Glycine was dissolved in water ,
2. Remaining amount of Glycine and PVP , MCC loaded in RMG and mixed,
3. Granulate the step-2 materials by using step-1 solution.
4. Wet mass of step -5 was dried to obtain granules,
5. Blended the granules obtained in step-4 with extragranular MCC and talc and
6. Compressed the blend into tablets.

Example 4

Procedure:

1. Fingolimod HC1 was dissolved in water
2. Loaded PVP, MCC in RMG and mixed
3. Granulated the step-2 materials by using step-1 solution.
4. Wet mass of step -3 was dried to obtain granules,
5. Blended the granules obtained in step-4 with extragranular MCC and talc and
6. Compressed the blend into tablets.

The table given below shows the stability data of.

Tablets prepared according to the present invention were tested for stability. Comparative stability data of fingolimod tablets of the present invention with commercially available Gilenya capsules is shown in the table given below:

It is clear from the tablet that the tablets of the present invention are comparable to the finanlimnH APT

We claim:

1. A stable tablet dosage form of fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative and one or more pharmaceutically acceptable excipients.

2. A stable tablet dosage form of fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative which comprises a zwitterion as a stabilizer and one or more pharmaceutically acceptable excipients.

3. The pharmaceutical composition according to claim 1, wherein the zwitterion is an amino acids, a phospholipid, and a sulfobetaine (NS).

4. The pharmaceutical composition according to claims 1 to 3, wherein the amino acid is selected from glycine, arginine, histidine, alanine, isoleucine, leucine, asparagine, lysine, aspartic acid, methionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, valine, ornithine, proline, selenocysteine, serine, tyrosine or a combination thereof.

5. The pharmaceutical composition according to claims 1 to 3, wherein the phospholipid is selected from phosphatidyl choline, phosphatidyl ethanolamine, sphingomyeline, lysophatidylethanolamine, cerebrosides, dimyristoylphosphatidyl choline, dipalmitotylphosphatidyl choline, distearyloylphosphatidyl choline, dielaidoylphosphatidyl choline, dioleoylphosphatidyl choline, dilauryloylphosphatidyl choline, l-myristoyl-2-palmitoyl phosphatidyl choline, l-palmitoyl-2-myristoyl phosphatidyl choline, 1 -palmitoyl-phosphatidyl choline, 1 -stearoyl-2-palmitoyl phosphatidyl choline, dimyristoyl phosphatidyl ethanolamine, dipalmitoyl phosphatidyl ethanolamine, brain sphingomyelin, dipalmitoyl sphingomyelin, distearoyl sphingomyelin.

6. The pharmaceutical composition according to claims 1 to 3, wherein the Sulfobetaine is Dimethylsulfonioacetate.

7. The pharmaceutical composition according to claims 1 and 2, wherein one or more pharmaceutically acceptable excipient is selected from diluent, binder, disintegrant, surafactant, glidant, lubricant.

8. The pharmaceutical composition according to claim 7, wherein the diluent is selected from microcrystalline cellulose, powdered cellulose, lactose (anhydrous or monohydrate), compressible sugar, fructose, dextranes, other sugars such as mannitol, sorbitol, lactitol, saccharose or a mixture thereof, siliconised microcrystalline cellulose, calcium hydrogen phosphate, calcium carbonate, calcium lactate or mixtures thereof.

9. The pharmaceutical composition according to claim 7, wherein the binder is selected from polyvinyl pyrollidone, polyvinylpyrrolidone/vinyl acetate copolymer, polyvinyl alcohol, polymers of acrylic acid and its salts, starch, methylcellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxyl propyl cellulose, ethylhydroxyethylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose etc., maltrin, sucrose solution, dextrose solution, acacia, tragacanth, locust bean gum, gelatine, guar gum, starch, pregelatinised starch, partially hydrolysed starch, alginates, xanthan or polymethacrylate, or mixtures thereof.

10. The pharmaceutical composition according to claim 7, wherein the lubricant is selected from stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulphate, hydrogenated vegetable oil, hydrogenated castor oil, sodium stearyl fumarate, macrogols, or mixtures thereof.

11. The pharmaceutical composition according to claim 7, wherein the disintegrant is selected from crospovidone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose calcium or mixture thereof.

12. The pharmaceutical composition according to claim 7, wherein the glidants is selected from colloidal silica, magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.

13. A stable tablet dosage form comprising fingolimod or a pharmaceutically acceptable salt thereof or a phosphate derivative, 5 to 95% by weight of a zwitterion and one or more pharmaceutically acceptable excipients.

14. A stable tablet dosage form comprising fingolimod or a pharmaceutically acceptable salt thereof or a phosphate derivative, 5 to 95% by weight of a zwitterion selected from glycine, arginine, histidine, alanine, isoleucine, leucine, asparagine, lysine, aspartic acid, methionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, valine, ornithine, proline, selenocysteine, serine, tyrosine or a combination thereof and one or more pharmaceutically acceptable excipients.

15. A stable tablet dosage form comprising fingolimod or a pharmaceutically acceptable salt thereof or a phosphate derivative, 5 to 95% by weight of a zwitterion and at lease one pharmaceutically acceptable excipient selected from

a) diluent selected from microcrystalline cellulose, lactose monohydrate or mixture thereof;
b) binder selected from hydroxypropyl cellulose or povidone;
c) lubricants selected from stearic acid, magnesium stearate or calcium stearate.
d) disintegrant selected from crospovidone, sodium starch glycolate, croscarmellose sodium,
e) glidant selected from colloidal silica or talc.

16. A stable tablet dosage form comprising fingolimod or a pharmaceutically acceptable salt thereof or a phosphate derivative, prepared by direct compression, dry granulation including roller compaction.

17. A stable tablet dosage form comprising fingolimod or a pharmaceutically acceptable salt thereof or a phosphate derivative, prepared by a process which comprises : (a) mixing fingolimod or a pharmaceutical acceptable salts or a phosphate derivative thereof with zwitterion;

(b) optionally, granulating the mixture obtained in the step (a);
(c) mixing the mixture from the step (a) or, optionally, from the step (b) with a lubricant and
(d) compressing the blend into tablets.

18. A stable tablet dosage form comprising fingolimod or a pharmaceutically acceptable salt thereof or a phosphate derivative and a zwitterion as a stabilizer, wherein the total impurity of the composition is less than the total impurity of the composition containing only a sugar alcohol.

19. A stable tablet dosage form of fingolimod, with less % of acetamide impurity compared to Gilenya capsules.

20. A stable tablet dosage form of fingolimod, comprising less than 0.5% of acetamide impurity.